RxDoctor Payments Data

Darren Pearson, MD

Internal Medicine · Wilmington, NCNPI 1083613749

Payments from drug & device makers

$2,462in general payments, 2019–2025

Across 139 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$310
  • Amgen$285
  • Abbott$251
  • Pfizer$222
  • Merck$194
  • Johnson & Johnson$170
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,33095%
  • Education$201%
  • Gifts$1125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,686
Medicare patients
271
Services billed
2,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$16,637
MounjaroTirzepatide12$12,419
PaxlovidNirmatrelvir/Ritonavir11$1,368
Levothyroxine Sodium23$961
Rosuvastatin Calcium49$907
Mirtazapine13$478
Escitalopram Oxalate32$373
Amlodipine Besylate62$361
Duloxetine Hcl11$347
Potassium Chloride27$343
Torsemide16$282
Omeprazole17$280
Atorvastatin Calcium20$247
Metoprolol Succinate17$239
Gabapentin26$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$42$16,63721 claims
Lilly USA, LLCMounjaro$132$12,41912 claims
PfizerPaxlovid$222$1,36811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →